Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference
Contineum Therapeutics (NASDAQ: CTNM), a clinical-stage biopharmaceutical company focused on developing therapies for neuroscience, inflammation and immunology (NI&I) conditions, has announced its upcoming participation at the 2025 Leerink Partners Global Healthcare Conference.
The company's management will deliver a presentation on Tuesday, March 11th at 3:00 p.m. ET. Interested parties can access the audio webcast through the Investors section of Contineum's website, where a replay will also be made available.
Contineum Therapeutics (NASDAQ: CTNM), una società biofarmaceutica in fase clinica focalizzata nello sviluppo di terapie per condizioni di neuroscienze, infiammazione e immunologia (NI&I), ha annunciato la sua prossima partecipazione alla 2025 Leerink Partners Global Healthcare Conference.
La direzione dell'azienda presenterà un intervento martedì 11 marzo alle 15:00 ET. Le parti interessate possono accedere alla trasmissione audio tramite la sezione Investitori del sito web di Contineum, dove sarà disponibile anche una registrazione.
Contineum Therapeutics (NASDAQ: CTNM), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de terapias para condiciones de neurociencia, inflamación e inmunología (NI&I), ha anunciado su próxima participación en la 2025 Leerink Partners Global Healthcare Conference.
La dirección de la empresa realizará una presentación el martes 11 de marzo a las 3:00 p.m. ET. Las partes interesadas pueden acceder a la transmisión de audio a través de la sección de Inversores del sitio web de Contineum, donde también estará disponible una repetición.
Contineum Therapeutics (NASDAQ: CTNM)은 신경과학, 염증 및 면역학(NI&I) 관련 치료제를 개발하는 임상 단계의 생명공학 회사로, 2025 Leerink Partners Global Healthcare Conference에 참여할 것이라고 발표했습니다.
회사의 경영진은 3월 11일 화요일 오후 3시(ET)에 발표를 진행할 예정입니다. 관심 있는 분들은 Contineum의 웹사이트 투자자 섹션을 통해 오디오 웹캐스트에 접속할 수 있으며, 재생도 제공될 예정입니다.
Contineum Therapeutics (NASDAQ: CTNM), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies pour des conditions de neurosciences, d'inflammation et d'immunologie (NI&I), a annoncé sa prochaine participation à la 2025 Leerink Partners Global Healthcare Conference.
La direction de l'entreprise fera une présentation le mardi 11 mars à 15h00 ET. Les parties intéressées peuvent accéder au webinaire audio via la section Investisseurs du site web de Contineum, où un replay sera également disponible.
Contineum Therapeutics (NASDAQ: CTNM), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien für Neurowissenschaften, Entzündungen und Immunologie (NI&I) konzentriert, hat seine bevorstehende Teilnahme an der 2025 Leerink Partners Global Healthcare Conference angekündigt.
Das Management des Unternehmens wird am Dienstag, den 11. März um 15:00 Uhr ET eine Präsentation halten. Interessierte Parteien können über den Investorenbereich der Website von Contineum auf das Audio-Webcast zugreifen, wo auch eine Wiederholung verfügbar sein wird.
- None.
- None.
About Contineum Therapeutics
Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis, progressive multiple sclerosis and chronic pain, and PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis and depression. For more information, please visit www.contineum-tx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250303275278/en/
Steve Kunszabo
Contineum Therapeutics
Senior Director, Investor Relations & Corporate Communications
858-649-1158
skunszabo@contineum-tx.com
Source: Contineum Therapeutics, Inc.
FAQ
When is Contineum Therapeutics (CTNM) presenting at the 2025 Leerink Partners Conference?
How can investors access Contineum Therapeutics' (CTNM) Leerink Conference presentation?
What therapeutic areas does Contineum Therapeutics (CTNM) focus on?
What is the current development stage of Contineum Therapeutics (CTNM)?
